Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ARID1A G1450fs |
| Therapy | Tulmimetostat |
| Indication/Tumor Type | urinary bladder cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ARID1A G1450fs | urinary bladder cancer | sensitive | Tulmimetostat | Preclinical - Cell culture | Actionable | In a preclinical study, Tulmimetostat inhibited viability in 5/6 bladder cancer cell lines harboring ARID1A loss of function mutations including ARID1A G1450fs in culture (PMID: 38833522). | 38833522 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (38833522) | Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers. | Full reference... |